🇺🇸 FDA

Intelligence · Patent portfolio

IONIS PHARMACEUTICALS Patents

Full USPTO pharma patent portfolio for IONIS PHARMACEUTICALS — grant dates, expiration, and drug cross-links.

Patents
222
Expiring ≤24m
0

Quick answer

IONIS PHARMACEUTICALS has 222 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Page 3 of 5

  1. US 11084844

    Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11084859

    Targeted mutant interferon-gamma and uses thereof

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11078486

    Compounds and methods for reducing ATXN2 expression

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11078485

    Compositions comprising alternating 2′-modified nucleosides for use in gene modulation

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11072794

    Compositions and their uses directed to huntingtin

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11058709

    Methods of treating breast cancer

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11033570

    Modulation of Lnc05 expression

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11021710

    Compounds and methods for reducing FXI expression

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11001631

    Clec9A binding agents

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11000595

    Modulators of PCSK9 expression

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10988538

    Bispecific signaling agents and uses thereof

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10961271

    Methods of modulating KEAP1

    Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10927377

    Modulators of APOL1 expression

    Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10927372

    Compositions and methods for modulating apolipoprotein C-III expression

    Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10912792

    Compounds and methods for modulating angiotensinogen expression

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10906985

    Targeted engineered interferon and uses thereof

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10907160

    Methods for reducing LRRK2 expression

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10883104

    Compositions and methods for modulating apolipoprotein (a) expression

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10858657

    Methods for treating hypercholesterolemia

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10844379

    Conjugated antisense compounds and their use

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10837016

    Modulation of huntingtin expression

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10822369

    Compounds and methods for the modulation of proteins

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10815480

    Modulation of alpha synuclein expression

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10815483

    Compositions for modulating C9ORF72 expression

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10793855

    Compositions for modulating expression of C9ORF72 antisense transcript

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10793862

    Compositions and methods for modulating growth hormone receptor expression

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10774333

    Modulators of PNPLA3 expression

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10772906

    Modulation of Factor 11 expression

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10751419

    Method for synthesis of reactive conjugate clusters

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10683499

    Compositions and methods for modulating TTR expression

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10655129

    Compositions and their uses directed to huntingtin

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10619158

    Modulation of huntingtin expression

    Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10619157

    Cancer treatment

    Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10577607

    Modulation of DYRK1B expression

    Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10577604

    Methods for monitoring C9ORF72 expression

    Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10570169

    Conjugated antisense compounds and their use

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10557137

    Modulating apolipoprotein (a) expression

    Expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10538763

    Compounds and methods for modulation of DUX4

    Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10533175

    Compositions and methods for modulating Ataxin 3 expression

    Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10526604

    Modulation of nuclear-retained RNA

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10517953

    Modulators of PCSK9 expression

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10517889

    Modulators of SMAD7 expression

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10493092

    Antisense compounds

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10478448

    Methods and compositions for modulating apolipoprotein (a) expression

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10479993

    Modulation of signal transducer and activator of transcription 3 (STAT3) expression

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10478449

    2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10472629

    Methods and compositions for modlating apolipoprotein (A) expression

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10443052

    Compositions for modulating C9ORF72 expression

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does IONIS PHARMACEUTICALS have?

222 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do IONIS PHARMACEUTICALS patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.